Inotuzumab Ozogamicin - PF-05208773
Sponsor
Pfizer (Industry)
Overall Status
Approved for marketing
CT.gov ID
NCT03127605
Collaborator
(none)
Study Details
Study Description
Brief Summary
Inotuzumab Ozogamicin Expanded Access Program
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
|
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pfizer
ClinicalTrials.gov Identifier:
NCT03127605
Other Study ID Numbers:
- B193
First Posted:
Apr 25, 2017
Last Update Posted:
May 18, 2020
Last Verified:
May 1, 2020
Additional relevant MeSH terms: